Andrew Staron

a.k.a. Amyloid Andrew.
Newly minted hematologist at Boston University Medical Center. Former amyloid doc at the BU Amyloidosis Center. Hiking when I can.

[Andrew Staron @a_staron]

@frederickruberg examines imaging measurements as biomarkers for cardiac amyloidosis, with focus on reproducibility and clinical implications. @BU_Amyloidosis #AmyloidosisForum

[Andrew Staron @a_staron]

@BU_Amyloidosis team arrives at the @US_FDA for the #AmyloidosisForum: confronting challenges in this rare disease head-on. @vsanchorawala

[Andrew Staron @a_staron]

Expert discussant panel at the #AmyloidosisForum with the @FDA - all committed to reliable scientific advancement in #Amyloidosis - including @vsanchorawala from @BU_Amyloidosis.

[Andrew Staron @a_staron]

Isabelle Lousada and Kristen Hsu of @Amyloidosis_ARC kicking off the Amyloidosis Forum at the @FDA - accelerating drug development in amyloidosis.

[Vaishali Sanchorawala @vsanchorawala]

Panel discussion - very engaged audience. @BU_Amyloidosis @omarsiddiqi @a_staron

[Raj Chakraborty @rajshekharucms]

Exciting day at @US_FDA brainstorming prognostic factors and clinical trial endpoints in AL Amyloidosis!

[BU Amyloidosis Center @BU_Amyloidosis]

As the event comes to a close, we want to express our gratitude to our dedicated multidisciplinary team members for sharing their research during the conference. #ISA2024 #Amyloidosis @ISA_Amyloidosis

[Dra. Isabel Carvajal. @estelais]

💙Masterclass in Cardiac #Amyloidosis @MyASNC @NotNoninvasive @LPhillipsMD
Day 1⃣⭐️ Prognostic markers in amyloidosis by Andrew Staron @a_staron @BU_Amyloidosis
👉ATTR

[J Mark Sloan @Jmarksloan]

While we usually shrug it off as insignificant, the loss of the Y chromosome (mLOY) in men is associated with a much higher cancer mortality, CV mortality and all cause mortality than those without it.
Possible association with ATTR amyloidosis.
@BU_Amyloidosis

[Vaishali Sanchorawala @vsanchorawala]

Significant and exciting news! Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201. With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL amyloidosis to the US. @BU_Amyloidosis
https://t.co/Wavs4WwD5l

[Vaishali Sanchorawala @vsanchorawala]

Increase awareness, decrease educational gap to diagnose early and improve outcomes. High clinical index of suspicion when red flag symptoms/signs/syndromes present is crucial.

[Andrew Staron @a_staron]

@vsanchorawala @BU_Amyloidosis @BWHAmyloid

[Vaishali Sanchorawala @vsanchorawala]

Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At @BU_Amyloidosis, 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! @a_staron

[BU Amyloidosis Center @BU_Amyloidosis]

February is Rare Disease Awareness Month! This month is all about public, medical, & political #amyloidosisawareness. Not only is it critical to let more people know about diagnostics and treatments that already exist but to create momentum for the development of new discoveries.

[Vaishali Sanchorawala @vsanchorawala]

Do not start plasma cell directed therapies till diagnosis of AL Amyloidosis is confirmed by accurate identification of the precursor protein #ASH22 #amyloidosis @Amyloid_Planet

[Andrew Staron @a_staron]

@MayaAbdallah_MD @ASH_hematology That's me... and I also see @josejacevedo !!!

[Vaishali Sanchorawala @vsanchorawala]

Daratumumab in AL amyloidosis
@awechalekar
https://t.co/5S1V6xajnC

[Andrew Staron @a_staron]

@MayaAbdallah_MD @ASH_hematology @cdumonti @BUHemeOncFellow Wow! Congrats 👏

[BU Amyloidosis Center @BU_Amyloidosis]

Save the date to hear from four of our incredible @BU_Amyloidosis clinicians during a live webinar hosted by @Amyloidosisfdn! Register for Updates in ATTR Cardiac and Neurological Amyloidosis at 12:00 pm ET on Friday, October 28 by visiting https://t.co/7D8qeFqhJw